How has been the historical performance of Ajooni Biotech?

Answer:The historical performance of Ajooni Biotech shows significant growth in net sales and profitability over the years, particularly from 2021 to 2025. Breakdown: Ajooni Biotech's net sales have increased from 51.04 Cr in March 2021 to 114.69 Cr in March 2025, indicating a strong upward trend. Total operating income followed a similar trajectory, rising from 40.09 Cr in March 2020 to 114.69 Cr in March 2025. The company's total expenditure also grew, reaching 111.01 Cr in March 2025 from 38.93 Cr in March 2020. Operating profit (PBDIT) has shown fluctuations, peaking at 5.75 Cr in March 2025, while profit before tax increased significantly from 0.48 Cr in March 2020 to 4.33 Cr in March 2025. Profit after tax also saw a substantial rise, reaching 3.37 Cr in March 2025 compared to 0.35 Cr in March 2020. The company's total assets grew from 22.94 Cr in March 2020 to 94.67 Cr in March 2025, while total liabilities increased from 22.94 Cr to 94.67 Cr in the same period. Cash flow from operating activities has been negative in 2025 at -17.00 Cr, contrasting with a positive cash flow of 22.00 Cr in 2024. Overall, Ajooni Biotech has demonstrated robust growth in sales and profitability, despite some challenges in cash flow management in recent years.